Provisional Patent Filed · Seed Round Open

Heart Failure
Decoded by
Your Genome

Genomix AI uses whole-genome deep learning to find the exact genetic root cause of your heart failure — delivering a personalized treatment plan in 14 days, not 18 months.

100K+
// patients trained
75%
// outcome improvement
$40K
// saved per patient/yr
⚠ High-Risk Variant Detected
rxscore_analysis.genomix
 LIVE
🧬
James, 52 — HFrEF
EF: 35% · WGS processed · Day 14
// Genetic Risk Drivers
HLD
25.7%
Kinase
18.1%
HTN
16.9%
BMI factor
13.3%
💊 RxScore™ Recommendation
ARNI (sacubitril/valsartan) superior to ACE inhibitor in HFrEF: EF improvement +3.2pts over standard care. 📖 McMurray et al., PARADIGM-HF, NEJM 2014 — 8,442 patients. LMNA variant guidance: Arbustini et al., JACC 2013.
Projected EF recovery35% → 52%
The Problem

A Genetic Crisis
Treated with a Blunt Instrument

6.5 million Americans live with heart failure. Half have a genetic root cause. Every single one gets the same trial-and-error protocol — built for the average patient, which helps no one.

6.5M
Heart failure patients in the United States
1M+
New diagnoses every year
50%
Cases with a genetic root cause
$31B
Annual US healthcare burden
The $165K Trial-and-Error Journey
🏥
Month 1 — First Hospitalization
Generic beta-blocker + ACE inhibitor started. No genetic workup. Patient discharged with zero personalized guidance.
// $15,000 cost
⚠️
Month 3 — Side Effects, Medication Switch
Severe fatigue and dizziness. ACE → ARB. Diuretic added. 2nd ER visit. Still no personalized data.
// $15,000 additional cost
📉
Month 8 — Second Hospitalization
Readmitted with uncontrolled fluid retention. 4th medication combination. EF barely moved: 35% → 37%.
// $25,000 cost · 3 weeks missed work
❌
Month 18 — Still No Answer
5th regimen. Genetic test finally ordered — 2-year wait. NYHA Class III. Quality of life destroyed.
// $125K+ lost productivity
Patient Story

Meet James — Before & After
Genomix AI

Same patient. Same diagnosis. Completely different life — because of genetics.

vs
👤
James, 52
Construction Manager
⚠ Standard Care
Diagnosis
HFrEF · EF: 35%
Risk Factors
HTN · High Cholesterol · BMI 31
Family History
Father: early MI
Genetics
No workup ordered
Approach
Trial & error · Generic protocols
$165K+
18-month total cost
Month 1
🏥
First Hospitalization
Admitted with shortness of breath. Diagnosed HFrEF. Started on generic beta-blocker + ACE inhibitor — no genetic workup ordered. Treated by population-average protocol.
→ Discharged. No personalized guidance.
Month 3
⚠️
Side Effects — Medication Switch
Severe fatigue and dizziness. ACE inhibitor → ARB. Diuretic added. Second ER visit. Cardiologist uncertain — no genetic data to guide the decision.
→ $15,000 additional cost. Still guessing.
Month 8
📉
Second Hospitalization
Readmitted. 4th medication combination tried. EF barely moved: 35% → 37%. Misses 3 weeks of work. Family under severe financial strain.
→ $25,000 cost. 3 weeks missed work.
Month 18
❌
Still No Optimal Treatment
5th regimen. Genetic test finally ordered — 2-year wait. Financially depleted. NYHA Class III. Quality of life severely compromised.
→ EF: 37%. $125K+ lost. Severe QoL impairment.
👤
James, 52
Construction Manager
✶ Genomix AI Enrolled
Diagnosis
HFrEF · EF: 35%
Genomix AI Plan
Protect Heart
RxScore™ Top Driver
LMNA · HLD Kinase 25.7%
Drug-Gene Match
94% — ARNI + Statin
Approach
Precision GDMT · Day 14
RxScore™ Risk Drivers
HLD
25.7%
Kinase
18.1%
HTN
16.9%
$38K
12-month total cost
Day 14
🧬
RxScore™ Complete — Genetic Profile Decoded
LMNA kinase variant and hyperlipidemia identified as dominant HF drivers. Personalized GDMT protocol generated. Drug-gene incompatibilities flagged before first prescription.
✓ Targeted therapy on day 1. Zero guesswork.
Month 2
💊
Optimal Medication — First Try
ARNI selected over ACE based on drug-gene profile. Statin optimized for HLD kinase variant. Zero side effects. Full therapeutic dose tolerated immediately. No ER visits.
✓ EF: 35% → 42%. Zero ER visits.
Month 5
📡
Continuous Monitoring — Early Alert
Protect Heart monitoring flags early fluid retention signal at week 18. Cardiologist intervenes proactively before exacerbation. James works full-time throughout.
✓ 0 hospitalizations. $40K avoided.
Month 12
✅
Sustained Optimal Outcomes
EF restored to 52% — near-normal cardiac function. Stable regimen, zero medication switches. NYHA Class I. Physical function top 25% for age group. Quality of life fully restored.
✓ EF: 52%. 0 hospitalizations. QoL fully restored.
Metric
⚠ Standard Care
✶ Genomix AI
Hospitalizations (12 mo)
2
0
Medication switches
5
1
ER visits
3
0
Time to optimal Rx
18 months
0.5 months
EF improvement
+2%
+17%
Work days lost
31 days
2 days
Total 12-month cost
$165,000+
~$38,000 (76% ↓)
Quality of life (NYHA)
Class III — Poor
Class I–II — Good
The Process

From Genome to Guidance
in Days, Not Years

01
🧬
Genomic Intake
Patient submits existing genetic data or orders via our clinical portal. All major formats accepted — no re-testing needed if data exists.
→
02
🔬
Deep Variant Analysis
AI processes millions of variants against our large-scale clinical genomic training cohorts — identifying HF-specific risk drivers and pathway interactions.
→
03
⚡
RxScore™ Generated
Personalized risk profile built in hours — weighting genetic, clinical, and lifestyle factors. Drug-gene incompatibilities flagged before prescribing.
→
04
💊
GDMT Recommendations
Cardiologist receives actionable, guideline-directed treatment recommendations tailored to the patient’s genetic profile with evidence grading.
→
05
📡
Continuous Monitoring
Longitudinal tracking flags early deterioration signals — enabling proactive intervention before hospitalization. Model learns and improves continuously.
Core Technology

RxScore™ — Your Patient’s
Genomic Risk Blueprint

Six-factor personalized risk profile built from deep learning on 100,000+ HF patients. Results in hours, not years.

RxScore™
Risk Drivers
Hyperlipidemia (HLD)25.7%
Gene Kinase Pathway18.1%
Hypertension16.9%
BMI / Metabolic14.8%
Age & Comorbidities13.3%
Lifestyle Factors11.2%
🎯 Personalized Risk Score
HF stratification beyond population averages
💊 Treatment Guidance
Evidence-graded GDMT matched to genetic profile
🧪 Drug-Response Profile
Predict efficacy of 40+ HF medications pre-prescribing
📡 Monitoring Alerts
Longitudinal signals — intervene before hospitalization
Clinical Outcomes

Numbers That Change Lives

Validated on 100,000+ patients across large-scale clinical genomic cohorts.

50%
Reduced hospitalizations
vs. standard of care
>3mo
Faster path to optimal GDMT
time saved per patient
$40K
Cost avoided per patient / year
eliminating trial & error
75%
Outcome improvement rate
demonstrated in clinical data
Plans

Choose Your Protection Plan

From first detection to lifelong heart protection — a plan for every patient and every practice.

🔍
Early Detect
Catch the risk before symptoms strike. Know your genetic HF vulnerability and act early — before the first event.
$299/report
One-time genomic risk assessment
  • Full genomic HF risk report
  • Polygenic Risk Score (PRS)
  • 6-factor RxScore™ profile
  • Hereditary variant screening
  • Shareable PDF for your cardiologist
  • Treatment recommendations
  • Drug-gene interaction profile
  • Continuous monitoring
Most Popular
💊
Treat Right
Stop the guesswork. Get personalized GDMT guidance matched exactly to your genetic profile — get it right the first time.
$799/report
Includes full detection + treatment layer
  • Everything in Early Detect
  • Personalized GDMT recommendations
  • Drug-gene interaction profile
  • Medication tolerance prediction
  • Evidence-graded treatment options
  • Cardiologist-ready clinical brief
  • Continuous monitoring
  • Proactive alert system
🛡️
Protect Heart
Continuous genomic intelligence. Real-time monitoring and proactive alerts to stay ahead of every deterioration signal.
$149/mo
Includes all treatment features
  • Everything in Treat Right
  • Continuous monitoring dashboard
  • Proactive deterioration alerts
  • Monthly risk recalculation
  • EHR integration (HL7/FHIR)
  • Cardiologist portal access
  • Longitudinal outcome tracking
  • Multi-patient practice tools
🏥
Practice & Enterprise
For cardiology practices, health systems, and payers. Full-suite deployment with shared savings, EHR integration, and pharma partnerships.
Custom
Volume pricing · Annual contracts
  • Everything in Protect Heart
  • Multi-patient population dashboard
  • EHR / Epic / Cerner integration
  • Payer value-based contracting
  • Shared savings ROI reporting
  • Dedicated clinical support team
  • Custom SLA & HIPAA BAA
  • Pharma trial patient selection

All plans are HIPAA-compliant · 14-day free trial on all paid plans · Questions? Talk to our team →

Technology

Built on Proven Science
Backed by Real Data

🔬
Polygenic Risk Score Modeling
Multi-variant analysis across the entire genome — not just single-gene flags. Our PRS engine identifies pathway-level interactions that single-variant tests miss entirely.
🧠
Deep Learning Variant Interpretation
Trained on 100K+ HF patients with multimodal data: genomics, EHR, imaging. Processes millions of variants in hours. Continuously learns from new patient outcomes.
💡
Drug-Gene Interaction Prediction
Predicts medication efficacy and adverse events before prescribing — using pharmacogenomic data layered with HF-specific pathway models for 40+ cardiac drugs.
📈
Longitudinal Outcome Forecasting
Dynamic risk recalculation over time — model updates with each new lab value, medication change, or clinical event. Early warning system prevents hospitalizations proactively.
🔒 Provisional Patent Filed — “A Personalized AI Driven Genomics Platform for Heart Failure Management”
Training Cohort — 100K+ Patients
Population Genomic Cohort52,000+
Multi-Ethnic Clinical Cohort31,000+
HF Outcomes Registry17,000+
4M+
Genomic variants analyzed
40+
HF medications modeled
14 day
Turnaround from sample
HIPAA
Compliant & secure
Business Model

Two Phases to Dominance

Validate B2C with cash-pay executive health. Then scale B2B into payer value-based contracts, EHR-embedded clinical tools, and pharma trial optimization.

Phase 1 · Now
B2C Validation
Direct-to-Consumer · Cash Pay
🏥
Executive Health Clinics
Cash-pay genomic risk assessments for proactive health programs. No insurance required. $500–$1K per analysis via existing CPT code.
📊
Proprietary Data Flywheel
Every patient enrolled strengthens the model. Clinical outcomes create a self-improving proprietary dataset that deepens our competitive moat.
🔬
IRB Approval & Clinical Validation
200-patient proof-of-concept trial builds the evidence base required for FDA 510(k) and enterprise sales.
Phase 2 · Series A
Enterprise Scale
B2B · Value-Based Care
💼
Payers — Shared Savings Contracts
$40K/patient savings creates immediate ROI for payer contracts. Scalable value-based model with measurable claim reduction.
🏨
Providers — EHR-Integrated Tools
Embedded clinical decision support for hospital systems and cardiology practices. Reduces physician cognitive load, improves outcomes.
💉
Pharma — Precision Trial Selection
Genomic insights make trials ~3× more likely to succeed. We de-risk patient selection for every sponsor — a multi-billion dollar market.
The Team

Built by Clinicians
& Scientists

Deep expertise at the intersection of cardiology, genomics, and machine learning — dedicated to making precision medicine the standard of care.

👩‍⚕️
Jennifer Kwan
MD, PhD · Co-Founder & CMO
Cardiologist and clinical researcher specializing in heart failure and precision medicine. 10+ years of bedside experience watching patients cycle through trial-and-error drug regimens. Leads clinical translation, physician integration, and regulatory strategy.
✉ [email protected]
👨‍💻
Alok Jha
MS, PhD · Co-Founder & CSO
Computational genomics expert with deep expertise in polygenic risk modeling, machine learning, and large-scale genomic data analysis. Architect of the RxScore™ deep learning engine across multi-institutional clinical cohort data.
✉ [email protected]
Join the Waitlist

Be First to
Experience RxScore™

Whether you’re a cardiologist, patient, investor, or health system — early access spots are limited.

// No spam · Confidential · Used only for onboarding

You’re on the list.

Thank you. We’ll reach out within 48 hours to discuss early access to RxScore™ and our proof-of-concept trial.

// We’ll respond within 24 hours for enterprise inquiries

Demo request received.

Our team will reach out within 24 hours to schedule a personalized walkthrough of the Genomix AI platform.

// We’ll notify you when RxScore™ is available with a cardiologist near you

Thank you for sharing your story.

You’re on our patient waitlist. We’ll reach out when RxScore™ is available with a participating cardiologist near you.

// We’ll send full pitch materials within 24 hours

Pitch deck request received.

We’ll send full investor materials within 24 hours and follow up to schedule a call with the founding team.

HIPAA-conscious design
Provisional patent filed
Seed round open
14-day free trial